Medical research is the systematic study of human health and disease, with the goal of understanding how the body works, why diseases develop, and how to prevent or treat them. It spans everything from studying cells under a microscope to testing new treatments in thousands of volunteers. The field is massive: in 2024 alone, the U.S. National Institutes of Health had a budget of nearly $45 billion to fund research projects across the country.
The Three Main Types
Medical research generally falls into three broad categories, each building on the others.
Basic research explores the fundamental mechanisms of biology, disease, and behavior. Scientists working at this level aren’t trying to create a specific drug or treatment. They’re asking questions like “how does this virus enter a cell?” or “what triggers this gene to malfunction?” The answers form the foundation that everything else builds on.
Clinical research involves studying disease and testing treatments directly in people. This includes clinical trials (testing whether a new drug or device is safe and effective), behavioral studies, and outcomes research that tracks how well treatments work in real-world settings. Most clinical research aims to generate the data needed for regulatory agencies to approve a new treatment.
Translational research bridges the gap between the other two. It’s focused on turning laboratory discoveries into practical treatments that reach patients, and on feeding real-world clinical observations back to the lab to spark new investigations. These stages don’t follow a straight line. Findings at any point can loop back and reshape work at another stage.
How Clinical Trials Work
Clinical trials are the most visible form of medical research, and they follow a structured sequence of phases designed to answer increasingly specific questions.
- Phase I tests a new drug or treatment in a small group, typically 20 to 80 people. The primary goal is safety: researchers want to identify side effects and determine safe dosage ranges.
- Phase II expands to 100 to 300 participants. At this stage, the focus shifts to whether the treatment actually works, while continuing to monitor safety.
- Phase III involves 1,000 to 3,000 participants. These large trials confirm effectiveness, compare the new treatment against existing options, and collect enough data for regulatory approval.
- Phase IV happens after a drug is already approved and on the market. Researchers track how the treatment performs in the general population, looking for rare side effects or optimal ways to use it.
The process is long and the odds are steep. From the first time a drug is tested in humans to marketing approval, the median timeline is about 7.3 years, according to a study published in The Lancet Regional Health. And only about 13% of drug candidates that enter clinical trials ever make it to approval. An analysis of nearly 4,000 compounds found that 3,486 were discontinued along the way, with just 513 succeeding. That success rate has remained roughly between 10% and 20% for decades.
Observational vs. Interventional Studies
Not all medical research involves giving people a treatment. The two fundamental study designs differ in one key way: whether the researcher intervenes or simply watches.
In observational studies, researchers don’t change anything about participants’ lives. They observe natural relationships between factors and outcomes. For example, tracking whether people who eat more vegetables develop less heart disease over time. These studies can reveal important patterns but can’t definitively prove that one thing causes another, because other unmeasured factors could explain the results.
In interventional studies (experiments), researchers actively do something to one group and compare the results. The gold standard here is the randomized controlled trial, or RCT. Participants are randomly divided into two groups that should be identical in every way. One group receives the treatment, the other doesn’t. Because the only difference between the groups is the treatment itself, any difference in outcomes can be attributed to the intervention with much greater confidence. This is why regulatory agencies rely heavily on RCTs when deciding whether to approve new treatments.
Ethical Protections for Participants
Medical research involving people is governed by strict ethical standards. The World Medical Association’s Declaration of Helsinki, the most widely recognized set of international ethical principles, establishes that the rights and interests of individual participants can never be overridden by the goals of a study. Researchers have a duty to protect participants’ life, health, dignity, privacy, and confidentiality. Research may only proceed if the importance of the objective outweighs the risks and burdens to participants.
In the United States, every study involving human subjects must be reviewed and approved by an Institutional Review Board (IRB) before it begins. These independent committees examine the research plan, assess risks, and review the informed consent process to make sure participants’ rights are protected. IRBs also conduct periodic reviews as the study progresses, and they have the authority to audit the consent process or the conduct of the study if concerns arise.
Informed consent is central to the entire system. It’s not just a form to sign. The process requires that participants receive clear information about the study, have time to consider their options, get their questions answered, and voluntarily agree to take part. If anything about the study changes in ways that could affect a participant’s willingness to continue, they must be told. Consent documents must also disclose whether compensation or medical treatment is available if something goes wrong.
What Participating Looks Like
People join clinical research for different reasons. Some hope to access a promising new treatment before it’s widely available. Others want to contribute to scientific understanding of a condition they live with, or to feel more actively involved in their own health. Participants also gain detailed knowledge about their condition and often connect with support groups and resources they wouldn’t have found otherwise.
The risks are real, though. An experimental treatment might not work, might cause uncomfortable side effects, or might turn out no better than what’s already available. You could be assigned to the control group, which in some studies means receiving a placebo rather than the active treatment. Some research involves physical tests that carry their own risks, like an increased chance of falling during balance assessments. The time commitment can also be significant: extra medical appointments, longer visits, complex medication schedules, and sometimes hospital stays. And while confidentiality is taken seriously, people beyond the research team, such as study sponsors and safety monitors, may have access to your medical information.
How Research Is Funded
The largest single funder of medical research in the world is the U.S. National Institutes of Health. Its 2024 budget of roughly $45 billion supports thousands of research projects. About $37 billion of that goes to research conducted outside NIH’s own laboratories, funding scientists at universities, medical schools, and research institutions across the country and around the world. The remainder supports NIH’s own intramural research programs, training, and infrastructure.
Private industry, particularly pharmaceutical and biotech companies, funds a substantial share of clinical research as well, especially the later-phase trials needed for drug approval. Nonprofit organizations, philanthropic foundations, and other governments round out the funding landscape.
How AI Is Changing the Process
Artificial intelligence is beginning to reshape the earliest stages of medical research. Traditional drug discovery relies on labor-intensive experimentation, testing thousands of compounds through trial and error to find ones that might work. This process is slow, expensive, and yields uncertain results.
Machine learning algorithms can analyze vast datasets to spot patterns that human researchers might miss, predicting a compound’s effectiveness and toxicity with greater accuracy than traditional screening methods. AI-based approaches can also design entirely new compounds with desirable properties, rather than just modifying existing ones. In some cases, AI has identified promising drug candidates in a fraction of the time conventional methods would require. The technology doesn’t replace the clinical trial process that follows, but it has the potential to significantly shorten the years of work that happen before a drug ever reaches human testing.